Doctor, do you think the two abnormally strong control groups are not worth the management to investigate the implementation of the clinical trial? Or is opt-302 really dead and not worth doing another clinical trial (if it is due to the COVID-19 pandemic)? Why does the management seem to assume that the control group is so excellent?
Ann: Opthea Announces Decision to Discontinue Wet AMD Trials, page-61
Add to My Watchlist
What is My Watchlist?